ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has scheduled a board meeting for August 26, 2024, where the directors will review and approve the company’s interim results for the first half of 2024, and discuss the potential distribution of an interim dividend. The announcement highlights the commitment of the board, which includes a mix of executive, non-executive, and independent directors, to evaluate the company’s financial progress and shareholder returns.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
